Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum

Rhea-AI Summary

Anbio Biotechnology (NASDAQ: NNNN) announced its CEO will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on March 18, 2026. The session is a fireside chat where the CEO will discuss previously disclosed business updates, strategic initiatives, and product development with investors.

The appearance underscores Anbio's engagement with the investment community and its focus on broadening access to rapid diagnostics and advancing its product pipeline.

News Market Reaction – NNNN

-2.60%

2 alerts

-2.60% News Effect

-$87M Valuation Impact

$3.24B Market Cap

0.4x Rel. Volume

On the day this news was published, NNNN declined 2.60%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $87M from the company's valuation, bringing the market cap to $3.24B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Press release date: March 17, 2026 Forum date: March 18, 2026

2 metrics

Press release date March 17, 2026 Announcement of participation in KeyBanc Capital Markets Virtual Healthcare Forum

Forum date March 18, 2026 Scheduled KeyBanc Capital Markets Virtual Healthcare Forum participation

Market Reality Check

Price: $21.52 Vol: Volume 25,080 is below th...

low vol

$21.52 Last Close

Volume Volume 25,080 is below the 20-day average of 51,815, suggesting limited pre-news participation. low

Technical Shares trade below the 200-day moving average at 31.43, indicating a longer-term downtrend despite today’s gain.

Peers on Argus

Peers showed mixed moves, with ATRC and STAA down while AZTA, BLFS, and KMTS wer...

1 Down

Peers showed mixed moves, with ATRC and STAA down while AZTA, BLFS, and KMTS were up, indicating NNNN’s 6.39% gain is more stock-specific than sector-driven.

Common Catalyst One peer, KMTS, reported earnings, pointing to company-specific catalysts rather than a shared conference theme.

Market Pulse Summary

This announcement highlights Anbio’s engagement with investors through the KeyBanc Capital Markets V...

Analysis

This announcement highlights Anbio’s engagement with investors through the KeyBanc Capital Markets Virtual Healthcare Forum on March 18, 2026, focusing on previously disclosed strategy and product development. With shares at 21.5, well below the 52-week high of 55.65 and under the 200-day MA of 31.43, recent governance and auditor changes from prior 6-K filings frame the backdrop. Investors may watch for any new disclosures or shifts in guidance emerging from the event.

Key Terms

in-vitro diagnostic, IVD

2 terms

in-vitro diagnostic medical

"a global diagnostic company in in-vitro diagnostic (IVD) technologies"

In-vitro diagnostics are tests run on samples taken from the body—blood, urine, swabs or tissue—analyzed outside the body to detect disease, measure biomarkers or guide treatment decisions. Investors care because these tests generate sales, require regulatory approval and reimbursement, and can create recurring revenue and competitive advantage as they become standard tools in clinics and labs—like a specialized instrument that professionals rely on in their daily work.

IVD medical

"a global diagnostic company in in-vitro diagnostic (IVD) technologies"

IVD stands for in vitro diagnostic — tests, instruments and kits that analyze samples taken from the body (blood, saliva, tissue) outside the body, such as lab assays or home pregnancy tests. Investors watch IVDs because they drive recurring sales, depend on regulatory approval and insurance coverage to reach markets, and differences in accuracy, cost or availability can quickly affect a maker’s revenue and legal risk.

AI-generated analysis. Not financial advice.

FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, announced today that its CEO will participate in the upcoming KeyBanc Capital Markets Virtual Healthcare Forum on Wednesday, March 18, 2026.

Anbio’s CEO is scheduled to participate in a fireside chat and will have the opportunity to share the Company’s previously disclosed business updates, strategic initiatives, and product development with the investor community.

Anbio’s participation in the conference reflects the Company’s continued engagement with the investment community and supports its commitment to broadening access to rapid diagnostics, advancing its innovative product pipeline, and creating long-term value through improved patient outcomes.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of IVD products. It is an innovation-driven global diagnostic company offering a diverse portfolio of mature diagnostic assays and key platforms for biomarker detection. These solutions cater to point-of-care settings, laboratory, and over-the-counter applications, enabling healthcare providers and patients to access fast, reliable, and cost-effective diagnostic tools. With a global presence across the EU, APAC, Africa, and the Americas, the Company’s products detect biomarkers associated with critical medical domains, encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Designed for compatibility with multiple sample collection matrices, including serum, plasma, whole blood, feces, urine, and saliva, the product lineup facilitates efficient and reliable diagnostic testing across diverse patient populations and healthcare settings. By prioritizing innovation, affordability, and speed, Anbio aims to transform the global diagnostics landscape, fostering a paradigm shift towards personalized and decentralized diagnostic solutions.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are not guarantee of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict and many of which are beyond the control of Anbio. Actual results may differ from those projected in the forward-looking statements due to risks and uncertainties, as well as other risk factors that are included in the Company’s filings with the U.S. Securities and Exchange Commission. Although Anbio believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by Anbio or any other person that their objectives or plans will be achieved. Anbio does not undertake any obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. 

Contact:
connect@anbio.info

FAQ

When will Anbio (NNNN) present at the KeyBanc Capital Markets Virtual Healthcare Forum?

Anbio's CEO will present on March 18, 2026 in a scheduled fireside chat. According to Anbio, the session will allow management to review previously disclosed business updates, strategic initiatives, and product development with the investor community.

What topics will Anbio's CEO discuss at the March 18, 2026 KeyBanc forum?

The CEO will discuss business updates, strategic initiatives, and product development in a fireside chat. According to Anbio, remarks will reflect previously disclosed updates and focus on the company’s rapid diagnostics strategy and product pipeline progress.

How can investors access Anbio's (NNNN) KeyBanc Capital Markets virtual presentation?

Investors can access the session via the KeyBanc Virtual Healthcare Forum webcast or conference platform. According to Anbio, the CEO’s participation is virtual and investors should use KeyBanc’s event access details to view the fireside chat.

Does Anbio (NNNN) plan to announce new clinical or financial data at the KeyBanc forum on March 18, 2026?

No new data was announced in advance; the CEO will reiterate previously disclosed updates. According to Anbio, the fireside chat will cover strategic initiatives and product development but does not advertise new clinical or financial releases.

What does Anbio's (NNNN) participation in the KeyBanc forum signal to investors?

Participation signals continued investor engagement and outreach to broaden awareness of the company’s diagnostics pipeline. According to Anbio, the appearance supports its commitment to expanding access to rapid diagnostics and communicating strategic progress.

Will Anbio (NNNN) provide a replay or investor materials after the March 18, 2026 KeyBanc forum?

A replay or materials are commonly provided after such events, but none were explicitly stated in the announcement. According to Anbio, investors should monitor company communications or KeyBanc event resources for any posted replay or materials.